Surprise USFDA inspection at Gland Pharma Limited's Dundigal Facility

Gland Pharma Limited has announced that the United States Food and Drug Administration (US FDA) has conducted surprise inspection of the Company's Dundigal Facility at Hyderabad for Good Manufacturing Practices (GMP) between 22nd July, 2024 and 25th July, 2024.

The inspection was concluded with TWO (2) 483 Observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the US FDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 2003.95 as compared to the previous close of Rs. 2021.65. The total number of shares traded during the day was 8564 in over 1363 trades.

The stock hit an intraday high of Rs. 2045.00 and intraday low of 1976.90. The net turnover during the day was Rs. 17240905.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 USFDA SurpriseInspection GMP DundigalFacility Hyderabad